As such, our results suggest that the tandem-dual antigen targeting strategy will represent effective anti-neoplastic therapy may ultimately prevent relapse secondary to absence or loss of BCMA expression on the malignant MM cells. Here, TNFRSF17 is linked to Miyoshi myopathy.